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Background: Idiopathic intracranial hypertension (IIH) is a condition predominantly affecting 28 
obese women of reproductive age. Recent evidence suggests that IIH is a disease of 29 
metabolic dysregulation, androgen excess and an increased risk of cardiovascular morbidity. 30 
Here we evaluate systemic and adipose specific metabolic determinants of the IIH 31 
phenotype.  32 
Methods: In fasted, matched IIH (N=97) and control (N=43) patients, we assessed: glucose 33 
and insulin homeostasis and leptin levels. Body composition was assessed along with an 34 
interrogation of adipose tissue function via nuclear magnetic resonance metabolomics and 35 
RNA sequencing in paired omental and subcutaneous biopsies in a case control study. 36 
Results: We demonstrate an insulin and leptin resistant phenotype in IIH in excess to that 37 
driven by obesity. Adiposity in IIH is preferentially centripetal and is associated with 38 
increased disease activity and insulin resistance. IIH adipocytes appear transcriptionally and 39 
metabolically primed towards depot-specific lipogenesis. 40 
Conclusions: These data show that IIH is a metabolic disorder in which adipose tissue 41 
dysfunction is a feature of the disease. Managing IIH as a metabolic disease could reduce 42 
disease morbidity and improving cardiovascular outcomes.  43 
Funding: This study was supported by the National Institute of Health Research UK (NIHR-44 
CS-011-028), the Medical Research Council UK (MR/K015184/1) and the Midlands 45 





Idiopathic intracranial hypertension (IIH) is characterised by elevated intracranial pressure 48 
(ICP) and papilloedema typically manifesting as disabling daily headaches and visual 49 
disturbances which leads to permanent visual loss in up to 25% of patients (1–4). IIH 50 
predominantly occurs in obese women of reproductive age (greater than 90%), where 51 
incidence is increasing in line with the obesity epidemic (5). Consequently, IIH constitutes a 52 
substantial financial burden in the clinical setting (5). IIH incidence increases with rising body 53 
mass index (BMI), with disease activation often occurring following rapid weight gain (6, 7). 54 
Weight loss is therapeutic in IIH, with reduction in adiposity associated with reduction in ICP 55 
and improvements in headache and visual outcomes, suggesting a role of adipose tissue in 56 
IIH pathogenesis (8, 9).  57 
The aetiology of IIH remains unclear, and an unmet research priority (10). IIH is no longer 58 
regarded as a disease isolated to the central nervous system as IIH patients have double the 59 
risk of cardiovascular disease (CVD) compared with obese individuals (6, 11). Importantly, IIH 60 
is a condition of androgen excess, and like  in polycystic ovarian syndrome (PCOS) may 61 
contribute  to cardio-metabolic diseases including T2D and CVD (12–14). We hypothesize that 62 
metabolic perturbations, possibly emanating from adipose tissue, contribute to the increased 63 
CVD risk in IIH.  64 
In a large cohort of female IIH patients with active IIH, we assessed markers of systemic 65 
metabolic dysregulation and analyse adipose tissue distribution. We also aimed to identify 66 
underpinning molecular mechanisms through investigation of a unique cohort of IIH patients 67 
from which we investigated paired omental (OM) and subcutaneous (SC) adipose tissue 68 
function. Here we define the first detailed metabolic phenotype of IIH, and identify molecular 69 
mechanisms within adipose tissue that may contribute to CVD risk. We demonstrate that IIH 70 
patients have dysregulated systemic metabolism, in excess to that mediated by obesity, being 71 




Furthermore, SC adipose would appear to be transcriptionally primed for increased calorie 73 





Patient characteristics 76 
Patients with active untreated IIH (97) and control patients (43) were prospectively recruited. 77 
The IIH cohort were all female, aged 32.4 ± 7.8 years and obese (BMI 40.0 ± 6.5 Kg/m2 ), with 78 
raised lumbar puncture opening pressure (LP OP) (34.8 ± 5.7 cmCSF) and papilloedema. The 79 
control cohort were matched for BMI and gender but were older (Table 1). Baseline 80 
characteristics and characteristics of the sub-study cohorts can be found in Table 1 and 81 
supplemental figure 1. 82 
IIH patients have an insulin resistant phenotype 83 
Epidemiological data has suggested that IIH patients have an increased risk of type 2 diabetes 84 
mellitus (T2D) and cardiovascular morbidity, suggestive of systemic metabolic dysfunction (6). 85 
Hence, we evaluated markers of insulin resistance in IIH. Fasting insulin levels were elevated 86 
in IIH (IIH 18.1 ± 13.3 mlU/L vs controls 12.1 ± 6.7 mlU/L Mann-Whitney U, U=1421, p=0.0025, 87 
Fig 1B), with markers of insulin resistance elevated in IIH compared to controls (Homeostatic 88 
Model assessment 2 Insulin resistance (HOMA2-IR), 1.97 ± 1.44 vs 1.33 ± 0.74; p=0.0030, 89 
Fig 1C), higher β-cell function in IIH (HOMA2-%B scores of 163.6 ± 76.4 vs 128.6 ± 48.7; 90 
p=0.0097, Fig 1D) and lower insulin sensitivity in IIH (HOMA2-%S scores of 72.4±45.5  vs 91 
131.6±153.3; p=0.0030, Fig 1E), where these features are associated with a progression to 92 
T2D (15). Additionally, a higher proportion of IIH patients have insulin resistance, as defined 93 
by a HOMA2-IR>1.8, (IIH 47.5% vs controls 22.6%; p=0.0155, Fisher’s exact test) (16). Given 94 
that the control cohort is older than the IIH cohort, a multiple regression analysis was carried 95 
out on the HOMA2-IR results, taking both age and BMI into consideration. This analysis 96 
demonstrated that IIH patients had higher levels of insulin resistance (1.89±0.28 vs 1.51±0.26 97 
HOMA2-IR; p<0.0001, Fig S2). The fasting glucose (Fig 1A) and glycated haemoglobin 98 
(HbA1c) (Fig 1F) levels were comparable between IIH and control subjects, despite the 99 




inferred from the ICP, was evaluated, where the relationship between (LP OP and HOMA2-IR 101 
was weak (p=0.051, correlation coefficient (ρ)=0.12). 102 
We evaluated the lipid profile in IIH, a risk factor for cardiovascular morbidity (17). We 103 
demonstrate no differences in IIH fasted cholesterol (IIH 4.94 ± 0.91 vs controls 5.09±0.95 104 
mmol/L, t-test, t(133)=0.88, p=0.37, Fig 1G) and triglycerides (IIH 1.54 ± 1.01 vs controls 1.42 ± 105 
0.60 mmol/L, Mann-Whitney, U=1889, p=0.96, Fig 1H) compared to the controls. We also 106 
evaluated hepatic and renal function in the IIH and control subjects (Sub-study 1, table 1) 107 
and noted a number of differences in IIH, although levels remained within the normal clinical 108 
reference range. 109 
Obesity in IIH 110 
It is well established that adipose distribution is a determinant of insulin resistance and 111 
cardiovascular risk (18, 19). Given that our data demonstrates a greater degree of insulin 112 
resistance, we assessed the adipose distribution and lean mass in IIH patients (Sub-study 113 
2,table 1) (20). We determined that IIH patients have a similar total mass, fat mass and lean 114 
mass compared to control patients. However, when assessing the truncal region, the adipose 115 
depot most associated with metabolic risk and insulin resistance, we demonstrate increased 116 
fat (IIH 46.03±6.29 vs controls 42.66 ± 5.84 %, t-test, t(52)=2.037, p=0.046, Fig 2A) and lower 117 
truncal lean mass (IIH 52.27 ± 6.15 vs controls 55.97 ± 5.64 %, t-test, t(52)=2.304, p=0.025, 118 
Fig 2B) in IIH. Accordingly, there is an increased truncal fat to lean mass ratio in IIH patients 119 
(0.94 ± 0.30 vs 0.78 ± 0.19, Mann-Whitney U, U=24, p=0.0441; Fig 2C). No differences in limb 120 
fat (Fig 2D) and lean mass (Fig 2E) suggests preferential truncal adipose deposition in IIH. 121 
Obesity is associated with insulin resistance and intracranial pressure  122 
Previous work demonstrated that truncal adiposity correlates with LP OP in IIH, suggesting 123 
that adiposity is associated with IIH disease activity (8). In this larger IIH cohort we recapitulate 124 
this finding, demonstrating that LP OP correlated with total (p=0.016, ρ=0.37, Fig 2F) and 125 




insulin resistance in obese individuals, and is observed in the present IIH cohort, linking 127 
excess abdominal adiposity to insulin resistance in the IIH patients (p=0.0017, ρ=0.46, Fig 128 
2H) (20). 129 
IIH patients have comparative hyperleptinaemia  130 
The satiety adipokine leptin is strongly associated with obesity, insulin resistance and 131 
metabolic dysfunction, and has been proposed to be pathogenic in IIH (21, 22). Interpretation 132 
of previous leptin studies in IIH is limited by sample size, selection of the control cohorts and 133 
variable fasting status (21, 23–26). Here we compared both serum and CSF in IIH patients 134 
against a healthy control cohort to determine if leptin is altered, and assessed the relationship 135 
of leptin to markers of metabolic dysfunction. 136 
In the study cohort, we demonstrate elevated fasted serum leptin (IIH, 79.5±30.4 vs controls 137 
63.5 ± 14.9 ng/ml, Welch’s t-test t(63.09)=3.059; p=0.003 Fig 3A) in IIH patents compared to 138 
patients with obesity (matched gender and BMI (Fig S1)). A further sensitivity analysis, 139 
additionally matching the controls for age as well as gender and BMI, confirms raised serum 140 
leptin (IIH, 75.6 ± 30.4 vs controls, 63.5 ± 14.9, Welch’s test, t(59.20)=2.089, p=0.04, Fig S3A). 141 
This demonstrates that IIH patients have hyperleptinaemia in excess to that observed in 142 
obesity (27). Transport of leptin into the CNS is saturable at higher levels of serum leptin in 143 
obesity (28). In keeping with this there were no differences in CSF and serum/CSF ratio 144 
between IIH and control subjects (Fig 3B, C and Fig S3B and C). It is unlikely that 145 
hyperleptinaemia is driving disordered CSF dynamics in IIH as neither serum (Fig 3D) or CSF 146 
(Fig 3E) leptin levels correlated with LP OP in IIH.  147 
IIH hyperleptinaemia is likely a reflection of systemic metabolic dysregulation in IIH. We note 148 
that body fat percentage positively correlates with serum leptin in IIH patients (p<0.0001, 149 
r=0.74) as it does in obesity (28). Additionally, elevated serum leptin is known to impact β-cell 150 
function in obesity and in keeping with this, serum leptin is associated with  β-cell function in 151 




Assessment of paired subcutaneous and omental adipose tissue 153 
We show that adiposity, is associated with LP OP, a reflection of IIH disease activity (Fig 2). 154 
Loss of adiposity is disease modifying in IIH (8, 9). We have also demonstrated 155 
hyperleptinaemia in IIH in excess of that driven by obesity (Fig 3). In obesity, these factors 156 
are associated with disordered adipose tissue metabolism (27). Consequently, we 157 
hypothesised that in IIH, adipose tissue would display perturbed function and metabolism, in 158 
excess to that expected from obesity alone. In order to examine our hypothesis in detail we 159 
recruited IIH and control subjects undergoing bariatric surgery and collected matched 160 
abdominal subcutaneous and omental adipose tissue biopsies (patients matched for age, 161 
gender and BMI Fig S4) and conducted a series of in vitro, molecular and metabolic 162 
assessments to examine phenotype.  163 
Subcutaneous and omental tissue morphology  164 
Histomorphometric analysis compared adipose tissue (SC and OM adipose depots) between 165 
IIH and control subjects (matched age, gender and BMI Fig S4). IIH SC adipocytes (Fig 4C) 166 
had a similar cross sectional area compared to controls, with a similar distribution of adipocyte 167 
area (Fig 4D). However, IIH OM adipocytes are smaller than controls (IIH, 3286±176 vs 168 
controls, 4056 ± 342 μm2; t(16)=2.206, P=0.042; Fig 4E). In particular there was an increased 169 
frequency of adipocytes at an area of 1000μm2 (IIH 8.8 ± 1.7 vs controls 2.7 ± 1.2%; p<0.01) 170 
and at 2000μm2 (IIH 27.9 ± 2.6 vs controls 17.2 ± 3.9%; P<0.0001; Fig 4F) indicating an 171 
increased proportion of small adipocytes (ordinary two-way ANOVA followed by Sidak’s test, 172 
Row factor F(17,288)=87.82, p<0.0001). 173 
Adipocyte leptin hypersecretion in IIH 174 
We showed in Fig 3 that IIH is a state of hyperleptinaemia. Consequently, we assessed leptin 175 
secretion in ex vivo adipose tissue (IIH compared to matched controls, Fig S4) to determine if 176 
adipose leptin hypersecretion is contributing to the enhanced hyperleptinaemia. Consistent 177 




ng/ml/100mg; Welch’s test; t(11.47)=3.6; P=0.0039, Fig 5A), and OM (IIH 2.9±0.8 vs controls 179 
0.6 ± 0.1 ng/ml/100mg; Welch’s test; t(9.276)=2.917; P=0.016, Fig 5B) adipose tissue from IIH 180 
patients secretes more leptin compared to BMI matched controls. Although adipose leptin 181 
secretion is elevated in IIH, this is independent of gene expression (Ob gene (leptin) from RNA 182 
sequencing) (Fig 5C) and adipocyte size (Fig 4).  183 
IIH adipose tissue is transcriptionally primed for lipid accumulation 184 
We examined the transcriptional profile of SC adipose tissue in IIH patients compared to a 185 
control cohort matched for gender and BMI (Figure S4). RNA sequencing followed by 186 
differential gene expression analysis revealed 708 up-regulated and  696 down-regulated 187 
Refseq genes in IIH SC adipose tissue, based on p-values <0.05 (Fig 6A) where the genes 188 
can be found in supplemental spreadsheet 1. 189 
In order to identify signatures unique to IIH SC tissue we performed gene ontology analysis 190 
using DAVID (Fig 6C), where gene lists and statistics can be found in supplemental 191 
spreadsheet 2. Our analysis did not reveal gene pathways enriched in upregulated genes but 192 
revealed gene pathways prominently enriched in downregulated genes. Our results suggested 193 
that the enrichment for these pathways was mainly driven by the strongly downregulated 194 
ribosomal genes. Previous reports have linked suppression of the highly expressed rDNA 195 
gene transcription (ribosomal genes)  as a prerequisite to lipid accumulation and energy 196 
storage (30–32). Therefore, we specifically interrogated ribosomal subunit genes (33), highly 197 
expressed genes as well as gene sets regulated by caloric intake (34) and lipid biosynthesis 198 
for enrichment in IIH SC using GSEA gene ontology analysis (Figure 6 C, D). We find that in 199 
IIH SC, ribosomal genes are repressed, suggesting active energy storage (Fig 6 D). Moreover, 200 
IIH SC transcriptional profile was enriched for gene expression changes associated with 201 
caloric intake during lipid biosynthesis (Figure 6 F,G,). Both IIH SC and control SC are derived 202 
from patients who have undergone an overnight fasting (routine before surgery), thus gene 203 
expression profile in IIH SC consistent with caloric intake and active lipidogenesis is 204 




profile consistent with active lipogenesis, despite the lack of caloric intake, suggesting an 206 
uncoupling of lipidogenesis from actual caloric intake.  207 
 208 
IIH adipocytes have perturbed metabolism 209 
Given our findings of elevated levels of insulin resistance in IIH and the demonstration that 210 
genes associated with lipogenesis are upregulated in SC adipose tissue (Fig 6) we conducted 211 
non-targeted NMR metabolomics to provide insight into the metabolism of the IIH tissue 212 
compared to matched controls (Fig S4). NMR spectra analysis allowed identification of 29 213 
metabolites in explant cultured SC and OM adipose tissue (Table S1) and 34 metabolites in 214 
the respective culture media (Table S2).  215 
IIH SC adipose tissue secreted more glycerol compared to controls (inferred from media 216 
incubated with adipose tissue relative to media without adipose tissue added, IIH 157.3 ± 62.6 217 
vs controls 84.5 ± 37.0 ΔµM/100mg; Unpaired two-tailed t-test, t(18)=3.168, P=0.0053, Fig 7B). 218 
There was no difference in intracellular glycerol (Fig 7A), and therefore an increase in the 219 
secreted/intracellular glycerol ratio (0.58 ± 0.43 vs 0.27±0.16; Mann Whitney test, U=14, 220 
p=0.0052, Fig 7C), an indication of enhanced glycerol secretion. Similarly, IIH OM adipose 221 
tissue secreted more glycerol compared to controls (128.7±45.7 vs 79.4±33.6 ΔµM/100mg; 222 
unpaired t-test, t(17)=2.655, p=0.018, Fig 7E), without any alteration in intracellular glycerol 223 
(Fig 7D) and an increase in secreted/intracellular glycerol ratio (0.50 ± 0.18 vs 0.27  ± 0.11; 224 
unpaired two tailed t-test, t(17)=3.243, p=0.0045, Fig 7F). 225 
We additionally detected alterations in branch chained amino acid (BCAA) consumption, 226 
where the BCAAs, leucine and isoleucine, may be preferentially catabolised to lipogenic 227 
acetyl-CoA as previously shown to occur in adipocytes (35, 36). IIH SC adipose tissue 228 
displayed net uptake of both leucine (inferred from media incubated with adipose tissue 229 
relative to media without adipose tissue added, IIH -38.02 ± 40.76 vs control 22.62 ± 54.25 230 
ΔµM/100mg; t-test, t(18)=2.826, p=0.011, Fig 7H) and isoleucine (IIH -30.22 ± 25.21  vs 231 




intracellular isoleucine and leucine levels were not altered (Fig 7G, I).  We suggest that IIH 233 
SC adipose tissue could be catabolising these amino acids to support de novo lipogenesis. 234 
Conversely, IIH OM adipose showed no difference in uptake or intracellular isoleucine and 235 
leucine (Fig 7K-N).  236 
IIH OM adipose had elevated tissue pyruvate (23.63 ± 16.77 vs 4.58 ± 7.18 µM/100mg; Mann 237 
Whitney Test, U=13, p=0.0039, Fig 8D) with no change in tissue lactate (Fig 8E) and thus a 238 
decreased lactate to pyruvate ratio (145.0 ± 200 vs 544.9 ± 380.7; Mann Whitney Test, U=18, 239 
P=0.015, Fig 8F). We also show reduced uptake of pyruvate into the OM adipose (-226.1 ± 240 
100.0 vs -344.0 ± 101.7 ΔµM/100mg; T-test, t(17)=2.545, p=0.0209, Fig 8I) suggestive of 241 
reduced tissue pyruvate consumption. No difference in lactate secretion was detected 242 
between the groups.  In parallel, a reduction in tissue acetate was observed in the IIH OM 243 
adipose alongside reduced secretion in the same depot (166.5±75.22 vs 286.8±64.85 244 
µM/100mg; T-test, t(18)=3.829, p=0.0012, Fig 8M and 335.4±176.4 vs 800.9±414.6 245 
ΔµM/100mg; T-test, t(17)=3.247, Fig 8N). No differences were observed in the SC adipose 246 





IIH is a disease of elevated ICP predominantly amongst young women with obesity, where 249 
incidence is rising in line with global obesity trends. Epidemiological data has highlighted an 250 
increased risk of CVD in IIH in excess of that for obesity (6, 11). IIH has classically been 251 
regarded as a neuro-ophthalmic disease manifesting with headaches and risk of visual loss. 252 
Here, we provide the first evidence that IIH is a disease of systemic metabolic dysregulation 253 
with neuro-ophthalmic manifestations. The insulin resistance phenotype in IIH is congruent 254 
with the previously described androgen excess phenotype in IIH, where female androgen 255 
excess is linked to insulin resistance and T2D (14). Although our relatively young IIH cohort 256 
(mean age 32) does not meet the criteria for prediabetes, the presence of insulin resistance 257 
in 50% of the cohort as assessed by HOMAR-IR, coupled with altered β-cell function (HOMA 258 
B) indicates a risk for progression to prediabetes and T2D, particularly in later life. This has 259 
important clinical implications for patient care, as insulin resistance is a potentially modifiable 260 
risk factor for future cardiometabolic morbidity (37). 261 
IIH patients have hyperleptinaemia in excess of obese controls and endorsed by elevated 262 
adipose leptin secretion. Previous studies also demonstrated raised serum leptin in IIH, where 263 
leptin was proposed to be causative in raised ICP (21). However, the lack of elevated CSF 264 
leptin and no correlation between leptin and LP OP suggests that hyperleptinaemia is unlikely 265 
to be directly driving disordered CSF secretion in IIH patients. Rather, we suggest that 266 
hyperleptinaemia is a feature of systemic metabolic perturbation. Hyperleptinaemia is a 267 
feature of other metabolic conditions and is associated with systemic insulin resistance, where 268 
insulin is a known leptin secretagogue (38, 39). 269 
The relationship of the systemic metabolic perturbations in IIH to ICP dynamics and disease 270 
activity remains unclear. This study did not evaluate if the metabolic dysfunction was driving 271 
raised ICP and this requires further investigation. The metabolic phenotype in IIH does, 272 




system and eyes but a systemic metabolic disease. These metabolic features may be relevant 274 
to the previously documented, heightened CVD risk in IIH (6).  275 
Obesity is a feature of metabolic disease, associated with insulin resistance and 276 
hyperleptinaemia (40). Supporting the hypothesis that IIH is a disorder of systemic metabolic 277 
dysregulation we noted increased truncal adiposity, which correlates with ICP, insulin 278 
resistance and hyperleptinaemia. Crucially, we show that IIH patients have a greater 279 
proportion of truncal fat to lean mass, where excess fat mass is associated with insulin 280 
resistance (41). 281 
Truncal adiposity correlates with LP OP, a marker of IIH disease activity, this suggests that 282 
adiposity could be associated with disease activity. In support of this, previous studies have 283 
described reduction of truncal fat mass in association with disease remission (8, 9). It is 284 
however unknown if weight loss confers improvement of the metabolic phenotype in IIH. We 285 
were able to access a cohort of IIH SC and OM IIH tissue despite its scarcity, providing the 286 
invaluable opportunity to perform in depth analysis. We identified that IIH SC adipose displays 287 
a transcriptional profile consistent with active lipid biosynthesis following calorie intake, 288 
notable as both patients and controls were fasted at the time of the biopsy (30, 34). As such, 289 
these findings suggest that SC adipose tissue is geared for lipogenesis. We noted 290 
downregulation of highly expressed ribosomal genes. This is in keeping with  previous 291 
literature demonstrating that during active lipogenesis, adipose tissue down-regulates the 292 
transcription of highly expressed genes (such as ribosomal genes) (34). Our metabolomic data 293 
suggests IIH adipose metabolism is dysregulated compared to control obese adipose. SC IIH 294 
adipose shows increased capacity for uptake of branch chain amino acids (BCAA), where 295 
isoleucine and leucine catabolism could contribute up to a quarter of the lipogenic acetyl-CoA 296 
pool (35). These data propose that IIH SC adipose tissue can preferentially catabolise BCAAs 297 
to support increased lipogenesis, corroborating the transcriptomic data (34). Given the 298 
indicators of increased lipogenesis, the elevated glycerol secretion from IIH adipocytes is 299 




studies, and the insulin resistant phenotype we have noted in IIH, the increased glycerol 301 
secretion could reflect breakdown of excess glucose through glyceroneogenesis  within the 302 
SC adipose tissue (42). 303 
 Together these data could indicate that IIH patients are predisposed to gaining adipose mass, 304 
which is important to consider when IIH patients often experience an exacerbation or onset of 305 
symptoms following rapid weight gain (7, 43). Dynamic assessment of de novo lipogenesis in 306 
IIH SC adipose would help support this hypothesis.  307 
In OM adipose tissue we identified decreased pyruvate uptake coupled with increased tissue 308 
levels of pyruvate. This is in the context of unchanged tissue and media lactate levels 309 
suggesting this is not occurring due to sensitivity to hypoxia, but more likely a means of the 310 
cell maintaining favourable cytosolic redox homeostasis under challenging metabolic 311 
conditions. This is however occurring in the setting of reduced tissue acetate and acetate 312 
secretion. Taken together our novel tissue approach has revealed that in IIH the OM depot 313 
maintains a more efficient energy network whilst the SC depot shows more signs of metabolic 314 
dysfunction potentially contributing to disease pathophysiology and cardiovascular risk.   315 
The study findings are limited to adult women, rather than male (5% of IIH) or paediatric 316 
patients with IIH (5). By nature of the disease being prevalent during child bearing years, the 317 
cohort is relatively young and consequently further studies are now warranted to evaluate 318 
metabolic implications for a more aged IIH population where metabolic complications may be 319 
more severe. Our studies have found evidence of metabolic dysfunction compared to obesity 320 
despite a young age compared to controls (44). The typical young age of IIH patients is 321 
important as earlier intervention to modify cardiometabolic risk factors is likely to improve 322 
future mortality and morbidity from cardiovascular disease as seen in other conditions 323 
characterised by metabolic dysfunction (45, 46). The present study utilises a relatively small 324 
sample size compared other studies that assess more common diseases. Additionally our 325 




eliminate the possibility of larger sample sizes yielding different results. However, the data 327 
was strengthened by the detailed clinical phenotyping, as well as the notable number of IIH 328 
subjects considering that IIH is a rare disease. The results lay the foundation for a prospective 329 
in-depth metabolic assessment across the IIH life course. 330 
We provide the first description of detailed metabolic phenotyping in active IIH, defining 331 
contributions to cardiovascular risk and identifying adipose tissue mechanisms that may 332 
contribute to pathophysiology (Fig 9). Adiposity in IIH is preferentially truncal with SC 333 
adipocytes demonstrating increased leptin secretion and transcriptional priming for caloric 334 
storage and gaining adipose mass. We also note differential fuel utilisation in the OM adipose. 335 
The adipose phenotype described maybe contributing to insulin resistance and will need 336 
further evaluation.  These data indicate that IIH is likely a systemic metabolic disease with 337 
neuro-ophthalmic features rather than solely a neuro-ophthalmological disease. We have not 338 
determined the causal relationship between the metabolic derangement and intracranial 339 
pressure dysregulation in IIH and this would be worthy of future investigation. The metabolic 340 
phenotype is likely to explain the increased risk of cardiovascular disease and T2D in IIH. As 341 
IIH presents in early adulthood, modifying the metabolic aspects of the disease through 342 
addressing insulin resistance and managing cardiovascular risk factors, could improve patient 343 





Unless otherwise stated, materials are from Sigma-Aldrich, Poole, UK. 346 
Study Design 347 
A case control study comparing IIH with matched controls was conducted to assess the 348 
systemic metabolic profile: BMI, blood pressure, fasting glucose and insulin, cholesterol and 349 
triglycerides and leptin (serum and CSF).  Sub-study 1 evaluated the hepatic and renal profile 350 
and sub-study 2 evaluated the body composition and distribution (Figure 1 supplemental). 351 
Adipose tissue was then evaluated in separate IIH and control populations.  352 
Study population  353 
Young (16-55) female IIH patients with active IIH (papilloedema > grade 1 Frisen and LP 354 
opening pressure > 25cmCSF on the date of research assessment visit) were recruited. The 355 
clinical consequences of IIH were not evaluated in this study, rather underling systemic 356 
disease activity was assessed; hence IIH patients at any stage of disease were included in 357 
the present analysis given that they had active disease. Patients who had previously failed 358 
pharmacotherapy, undergoing pharmacotherapy (such as acetazolamide) or failed community 359 
weight management were included in the study given the presence of active IIH, thus the IIH 360 
cohort represents a cohort with active disease. Control patients met the same inclusion criteria 361 
as the IIH patients, where absence of IIH was confirmed. The control subject cohort was 362 
matched to the IIH population for age, gender and BMI. Gender was participant reported. 363 
Exclusion criteria 364 
Exclusion criteria for all patients included receiving hormone manipulating medication, 365 
significant comorbidities including known endocrinopathies and the inability to give informed 366 





All participants underwent detailed medical history and examination.  All blood samples were 369 
collected following an overnight fast (from midnight). Lumbar punctures were carried out in all 370 
IIH patients and conducted in the left lateral decubitus with knees bent at a 90° angle or more 371 
and lumbar puncture opening pressure (LP OP) recorded before CSF was collected (up to 372 
15ml). Serum samples not analyzed immediately were centrifuged (10 minutes at 1500 g at 373 
4°C) aliquoted and stored at -80 °C.  Cerebrospinal fluid (CSF) samples were centrifuged (800 374 
g for 10 minutes at 4°C) and the supernatant was aliquoted and stored at -80 °C. All samples 375 
processed only underwent a single freeze-thaw cycle. 376 
Clinical and biochemical analysis 377 
BMI was calculated from weight and height and using the following formula: BMI = (weight 378 
(kg) / height (m)2). Fasting glucose, glycated haemoglobin (Hb1Ac) and lipids were measured. 379 
In sub-study 1 subjects also had liver function (bilirubin, alkaline phosphatase (ALP) and 380 
aspartate amino transferase (AST)) and renal function tests (urea, creatinine and estimated 381 
glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease 382 
Epidemiology collaboration (CDK-EPI) equation). All tests were conducted in the biochemistry 383 
department at University Hospital Birmingham NHS Foundation Trust, UK.  384 
Fasting insulin and HOMA2-IR 385 
Fasting insulin was measured using commercially available assays (Mercodia, Uppsala, 386 
Sweden), according to the manufacturer’s instructions. Homeostasis model assessment of 387 
insulin resistance (HOMA2-IR) was calculated using the program HOMA calculator 388 
v2.2.3(www.dtu.ox.ac.uk/homacalculator). 389 
Body composition 390 
Duel energy x-ray absorptiometry (DEXA) was performed using a total-body scanner (QDR 391 
4500; Hologic, Bedford, MA, USA), as previously described (20, 47) on a sub set of patients. 392 
The scans were conducted by a clinical scientist and trained radiographer. Patients with metal 393 
prosthetics or implants were included, and tissue overlying the prosthesis was excluded from 394 
analysis. Scans were checked for accuracy of fields of measurement. Regional fat mass was 395 




of coefficients of variation (CV) was less than 3%, and for regional fat analyses it was less 397 
than 5%. Both the IIH and control cohorts were analysed on the same DEXA scanner. 398 
Additionally, a subset of patients had body fat percentage determined by bio-impedance via a 399 
Body Composition Analyser TANITA BC-418 MA. A 0.2kg correction was made for base layer 400 
clothing where a standard female body type pre-set was selected for all patients. The machine 401 
was used according to manufacturer’s instructions. 402 
Adipose tissue collection 403 
Adipose tissue from IIH patients was covered under the following ethical approvals 404 
(13/YH/0366 and 14/WM/0011). Bariatric control patients were identified from elective bariatric 405 
lists at Birmingham Heartlands Hospital NHS Trust who had no endocrinopathies and not on 406 
hormonal treatments under the following ethics approval (14/WM/0011). All patients were 407 
fasted overnight (from midnight) prior to adipose tissue biopsy. Adipose tissue (abdominal 408 
subcutaneous (SC)) and where possible omental (OM)) was biopsied and was either placed 409 
immediately in RNA later, into phenol free DMEM/F12 (Thermofisher, Paisley) without, UK 410 
antibiotics, or 4% formaldehyde.  411 
Histomorphometric analysis 412 
Adipose tissue was fixed in 4% formaldehyde prior to dehydration, clearing and embedding in 413 
paraffin wax. Embedded tissue was cut in 5 µm sections prior to a haematoxylin and eosin 414 
(H&E) stain.  Sections were imaged using a Leica DM ILM inverted microscope (Leica 415 
Microsystems UK Ltd, Milton Keynes, UK) though a Leica DFC290 camera (Leica) utilising 416 
the Leica application suite (V2.8.1, Leica).  Adipocyte area was assessed via the Image J 417 
(National Institutes of Health, Bethesda, MD) plugin Adiposoft (48). The evaluator was blinded 418 
to tissue type and patient disease state during analysis.  419 
RNA sequencing  420 
Stranded mRNA cDNA libraries derived from SC adipose tissue (insufficient omental tissues 421 
precluded this analysis) were sequenced at 2X100 paired end reads on the Illumina HiSeq 422 




comparable RNA integrity numbers quality (7.5 ± 0.82 vs. 7.7 ± 0.50, P=0.6), indicating 424 
suitable RNA integrity.  425 
Quality control on the RNA sequencing was performed with FastQC v0.11.4. Read and 426 
adapter trimming was carried out using TrimGalore! v0.4.4 with Cutadept v1.13 with default 427 
settings (49). RNA-seq reads were mapped to the human genome (hg19, UCSC annotation) 428 
utilising STAR software v2.5.3a with default parameters (50). Counts per gene were calculated 429 
using custom scripts acting in a HTSeqcount compatible mode with the following parameters: 430 
--format=bam --minaqual=10 --stranded=reverse –mode=union (51, 52). Differentially 431 
expressed genes were identified using the DESeq2 (v1.14.1) from Bioconductor release 3.3 432 
(53). Differentially expressed genes were called at a false discovery rate of 5%. Normalised 433 
FPKM values for each gene were calculated using DESeq2 and GenomicFeatures v1.26.4 434 
package (54). Gene set enrichment analysis was carried out as described previously 435 
described (55, 56). Interrogated gene sets can be found in supplemental spreadsheet 3,where 436 
gene sets were derived from the following articles (30, 33, 34). 437 
 438 
Data availability 439 
The accession code for RNA sequencing data is GEO database: GSE171398. 440 
Conditioned media protocol 441 
Adipose tissue had large blood vessels dissected out and was cut into ~100mg explants prior 442 
to a 24 hour incubation in phenol free DMEM/F12 with no antibiotics, in glass tubes (VWR) at 443 
37°C. Following incubation media was aliquoted and corresponding explant were stored at -444 
80°C prior to analysis.  445 
Metabolomics 446 
Nuclear magnetic resonance (NMR) based metabolomics provided a non-targeted 447 
metabolomics approach. Adipose tissue conditioned media 1 in 4 in NMR buffer (Final 448 
concentration: 100 mM sodium phosphate, 500 μM 4,4-dimethyl-4-silapentane-1-sulfonic acid 449 




underwent a methanol/water/chlorophorm extraction prior to retention and evaporation of the 451 
polar layer. Dried samples reconstituted in 60 μl of 100 mM sodium phosphate buffer 452 
containing 100% D2O and 500 μM DSS. All samples were transferred into 1.7 mm Bruker 453 
Sample Jet NMR tubes (Cortecnet, Voisins-Le-Bretonneux, France) via an automatic Gilson. 454 
Samples were run on a Bruker 600 MHz Bruker Avance III spectrometer (Bruker Biospin) with 455 
a TCl 1.7 mm z-PGF cryogenic probe set at 300K. 1D-1H-NMR spectra were obtained, where 456 
spectral width was set to 7,812.5. 457 
1D-1H-NMR spectra were processed using MetaboLab software (57). All 1D data sets were 458 
zero-filled to 131,072 data points prior to Fourier Transformation. The chemical shift was 459 
calibrated by referencing the DSS signal to 0 p.p.m. 1D-spectra were manually phase 460 
corrected. Batch baseline correction was achieved using a spline function. 1D-1H-NMR 461 
spectra were exported into Bruker format for metabolite identification and concentration 462 
determination using Chenomx 8.2 (Chenomx INC, Edmonton, Canada). All values obtained 463 
were normalised to the mass of the appropriate adipose tissue explant. Conditioned media 464 
values were made relative to media without adipose tissue. The investigator was blinded to 465 
patient type and tissue type during metabolite quantification. 466 
 467 
Leptin ELISAs 468 
Leptin was quantified in adipose conditioned media, serum and CSF using the human leptin 469 
DuoSet ELISA (DY-398,Bio-techne, Abingdon, UK). ELISA was carried out according to 470 
manufacturer’s instructions using recommended ancillary kit (Bio-techne, DY008). 471 
Conditioned media was diluted 1:50, Serum 1:100 and CSF 1:5 in reagent diluent. Samples 472 
were run in duplicate. Total secreted leptin was normalised to corresponding explant mass.  473 
Intra-assay variability CV 7.28 %, inter-assay variability CV 8.2% for conditioned media assay. 474 
Serum intra-assay variability CV 2.71 % and inter-assay variability CV 6.99 %. CSF yielded 475 
intra-assay variability CV 3.85 % and inter-assay variability CV 8.9%. 476 




Statistical analysis was performed using Graphpad prism 8 (Graphpad Software Inc, La Jolla, 478 
CA, USA) and SPSS 24 (SPSS Inc, Chicago, IL, USA). Data presented as mean ± standard 479 
deviation unless otherwise stated. Data normality was assessed by a Shapiro-Wilk normality 480 
test. Where data was normally distributed unpaired two-tailed t-tests (equal variance) or 481 
Welch’s test (unequal variance) were employed, whereas non-parametric data was assessed 482 
via Mann-Whitney U. Spearman’s rank correlation coefficient (ρ) and Pearson’s correlation 483 
coefficient (r) was used for assessing correlations in the IIH cohorts. Where data points are 484 
missing, data was not imputed. We did not correct for multiple comparisons as this would have 485 
increased the likelihood of type II errors with the exception of RNA sequencing data. Results 486 
were judged significant at P<0.05. 487 
 488 
Study approval 489 
IIH subjects were identified from multiple UK centres and samples were collected following 490 
informed, written consent. The trials received ethical approval from the York and Humber-491 
Leeds West Research Ethic committee (REC) (13/YH/0366), Dudley local REC (06/Q2702/64) 492 
and the Black Country REC (14/WM/0011). 493 
Control patients were recruited via advertisement, where sample collection occurred following 494 
informed, written consent. Sample collection was approved by the South Birmingham Local 495 
REC and the Black Country REC (14/WM/0011). Control patients for adipose tissue 496 
experiments were recruited from elective NHS bariatric surgery lists following written informed 497 
consent and was approved by the Black Country REC (14/WM/0011). 498 
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Figure 1) Perturbed metabolic function in IIH 664 
Histograms of fasted glucose (A), insulin (B), HOMA2-IR (C), HOMA2-%B (D), HOMA2-%S 665 
(E), HbA1C (F), Cholesterol (G) and Triglycerides (H) in control (n=43) and IIH patients (n=97). 666 
Grey boxes represent healthy clinical reference ranges. A and F dotted lines represent 667 
thresholds suggestive of type 2 diabetes mellitus. C dotted line represents HOMA2-IR score 668 
1.8, threshold for insulin resistance. N represents an individual patient. Data presented as 669 





Figure 2) IIH patients have an altered body composition 672 
IIH and control patient body composition assessed via dual x-ray absorptiometry (DEXA) 673 
scanning. Histograms of (A) Truncal fat percentage, (B) truncal lean percentage, (C) truncal 674 
fat/lean ratio, (D) limb fat percentage and (E) limb lean percentage. A-E, n=27 for control and 675 
IIH. Scatter graphs of LP Op vs (F) total body fat (n=47) and (G) truncal fat mass (n=47), and 676 
(H) HOMA2-IR vs total fat mass (n=44) in IIH patients. N represents an individual patient.  677 
Unpaired t-test for B-D. Manny-Whitney test for A,E. Spearman’s correlations for F-H. Data 678 





Figure 3) IIH patients display an enhanced hyperleptinaemia 681 
Fasted leptin levels assed by ELISA in IIH and control patients. Serum leptin (A) in control 682 
(n=19) and IIH patients (n=60). CSF leptin in IIH (N=87) and control (N=20) patients (B). 683 
Serum/CSF ratio in control (n=19) and IIH (n=58) patients (C). Scatter graph of lumbar 684 
puncture opening pressure (LP Op) vs serum leptin (D) and CSF leptin (E). N represents an 685 
individual patient. Welch’s t-test for A and Mann-Whitney test for B and C. Pearson's 686 





Figure 4) Histomorphometric analysis of IIH adipose tissue. 689 
Micrographs of paired paired subcutaneous (SC) (A) and omental (OM) (B) adipose tissue 690 
from age sex and BMI matched control  and IIH  patients. Mean adipocyte (C) and adipocyte 691 
area frequency (D) SC adipocyte area in control (n=7) and IIH (n=8). Mean OM adipocyte area 692 
(E) and adipocyte area frequency (F) in control (n=7) and IIH (n=11). N represents an 693 




Sidaks multiple comparison test for D and F. Data presented as mean±SD for C and E and 695 
mean±SEM for D and F, *=p<0.05,*=p<0.01, ****=p<0.0001. 696 






Figure 5) Adipocyte leptin hypersecretion in IIH 700 
Leptin secretion assessed from ex vivo adipose tissue via ELISA in control and IIH patients. 701 
(A) Leptin secretion from SC adipose tissue in controls (n=12) and IIH (n=11). (B) Leptin 702 
secretion from OM adipose tissue in controls (n=8) and IIH (n=10). (C) LEP gene expression 703 
in subcutaneous adipose tissue. N represents and individual patient. Welch’s t-test for A and 704 
B, t-test for C. Data presented as mean±SD, *=P<0.05, **=P<0.01. 705 






Figure 6) IIH SC adipose tissue displays a distinct transcriptome 709 
Differential gene expression (DGE) analysis of SC adipose tissue from control vs IIH patients. 710 
(A) Bar plot displaying the number of differentially expressed Refseq genes at p<0.05. (B) 711 
Gene ontology for significantly downregulated genes in IIH adipose. Gene set enrichment 712 
analysis of (C) Ribosomal subunits, (D) Lipid Biosynthesis, (E) Caloric Intake Up and (F) 713 
Caloric Intake Down against differential expression data from adipose tissue of control vs IIH 714 
patients. NES= normalised enrichment score, FDR= False Discovery Rate. The green line 715 
represents the accumulation of genes in the indicated gene list against the expression pattern 716 
in control vs IIH patients (Blue- downregulated in samples from IIH, red- upregulated in 717 





Figure 7) IIH adipose displays features of altered lipid metabolism 720 
NMR based metabolomics on paired SC and OM adipose tissue explants and corresponding 721 
media in control and IIH patients. Tissue and media levels of glycerol in SC (n=10) (A-C) and 722 
OM (control n=9, IIH n=10) (D-F). Tissue and media levels of leucine and isoleucine in SC (G-723 
J) and OM (K-N) adipose tissue N=10. N represents a single patient’s adipose explant or 724 
corresponding media. T-tests and Mann-Whitney tests. Data presented as mean±SD, 725 





Figure 8) IIH OM adipose tissue displays features of altered nutrient utilisation 728 
NMR based metabolomics on paired SC and OM adipose tissue explants and corresponding 729 
media in control and IIH patients. Tissue concentrations of pyruvate, lactate and 730 
pyruvate/lactate ratio in SC (A-C) and OM (D-F) adipose tissue. Media exchange of pyruvate 731 
and lactate in SC (G-H) and OM (I-J). Tissue concentration and media exchange of acetate 732 
in SC (K-L) and OM (M-N) adipose tissue. N represents a single patient’s adipose explant or 733 
corresponding media. T-tests and Mann-Whitney tests. Data presented as mean±SD, 734 





Figure 9) IIH metabolism concept figure 737 
IIH patients display systemic and tissue level metabolic disruption in excess to that conferred 738 
by obesity. IIH patients are insulin resistant and display hyperleptinaemia, where they have 739 
increased abdominal obesity. IIH adipose tissue displays leptin hypersecretion, and features 740 





Table 1) Characteristics of IIH and control subjects  743 
Characteristics Control IIH 
Number (N) 43 97 
Sex (% female) 100 100 
Age (years) 45.5 ± 8.8**** 32.4 ± 7.8 
BMI (kg/m2) 39.0 ± 4.5 40.0 ± 6.5 
Systolic BP (mmHg) 127.9 ± 18.26 126.4 ± 14.67 
Diastolic BP (mmHg) 75.35 ± 10.4 74.86 ± 11.13 
LP OP (cmCSF) N/A 34.8 ± 5.7 
Fasting glucose (mmol/L) 4.71 ± 0.53 4.82 ± 0.86 
Fasting insulin (mlU/L) 12.1 ± 6.7** 18.1 ± 13.3 
HOMA2-IR 1.33 ± 0.74** 1.97 ± 1.44 
HOMA2-%B 128.6 ± 48.7** 163.6 ± 76.4 
HOMA2-%S 131.6 ± 153.3** 72.4 ± 45.5 
HbA1c 36.8 ± 5.5 35.8 ± 4.4 
Cholesterol 5.10 ± 0.96 4.94 ± 0.91 
Triglycerides 1.42 ± 0.61 1.54 ± 1.01 
Sub study 1: Hepatic 
and renal profile 
  
Number (N) 25 14 
Age (years) 41.6 ± 4.9 39.3 ± 6.8 
BMI (kg/m2) 35.5 ± 3.5 36.7 ± 6.0 
ALP (U/L) 117 ± 34.5* 160.2 ± 57.0 
LP OP (cmCSF) N/A 36.7±4.2 
AST (U/L) 16.4 ± 6.4 20.5 ± 7.5 
Bilirubin (U/L) 4.4 ± 2.8** 7.6 ± 4.0 
Urea (mmol/l) 4.04±0.95 3.99±0.73 
Creatinine (μmol/L) 81.5±5.6** 88.3±6.4 
eGFR (ml/min/1.73m2) 77.38±7.35* 71.44±7.4 
Sub study 2: DEXA 
profile 
  
Number 27 27 
Age (years) 39.5 ± 4.9 37.2 ± 5.1 
BMI (kg/m2) 35.0 ± 4.4 36.8 ± 7.2 
LP OP (cmCSF) N/A 34.8±5.2 
Total fat (kg) 40.2 ± 10.2 42.7 ± 11.6 
Truncal fat (kg) 20.1 ± 5.9 22.4 ± 7.4 
Limb fat (kg) 19.3 ± 4.7 19.3 ± 5.2 
Total lean (kg) 50.1 ± 6.7 49.3 ± 7.7 
Truncal lean (kg) 25.7 ± 3.4 24.0 ± 4.2 
Limb lean (kg) 21.6 ± 3.4 22.2 ± 3.8 
Total bone (kg) 1.79 ± 0.29* 1.99 ± 0.30 
Truncal bone (kg) 0.63 ± 0.12*** 0.76 ± 0.15 
Limb bone (kg) 1.16 ± 0.20 1.21 ± 0.18 
BMI= Body mass index, BP= Blood pressure, LP OP= Lumbar puncture opening pressure, 744 
HOMA2-IR= Homeostatic model assessment 2- Insulin resistance, HOMA2-%B= HOMA- beta 745 
cell function, HOMA2-%S= HOMA- Insulin sensitivity, HbA1c = Glycated haemoglobin, ALP= 746 
Alkaline phosphatase, AST= Aspartate transaminase, eGFR= estimated glomerular filtration 747 
rate. Data presented as mean ± SD. *=p<0.05, **=p<0.01, ***=p<0.001 and ****=p<0.0001. 748 
